Welcome | About Us | Consultancy | CNS Experimental Medicine | Why P1vital | Publications |
P1vital CNS Biomarkers | P1vital^® Oxford ETB | Consortium | Contact Us | Careers | Links

CORPORATE

• P1vital Overview brochure
• P1vital and Hammersmith Medicines Research Collaboration
• Consortium press release

REVIEWS

• Kumar, P., Harmer, C.J. and Dourish, C.T. (2013). Neuroimaging Approaches to the Understanding of Depression and the Identification of Novel Antidepressants. Brain Imaging: Translational Tools for CNS Drug Discovery, Development and Treatment (Edited by R. A. McArthur), Elsevier, pp. 343-411.
• Dawson, G.R., Dourish, C.T. and Goodwin, G.M. (2011). Editorial: Special issue on CNS Experimental Medicine. Journal of Psychopharmacology, 25, 1145-1147.
• Dawson, G.R, Craig, K. J., Dourish, C.T. (2011). Validation of experimental medicine methods in psychiatry: The P1vital approach and experience - Biochemical Pharmacology 41,1435-1441
• Dourish, C.T., Wilding J.P.H. and Halford, J.C.G. (2008). Anti-obesity Drugs: From Animal Models to Clinical Efficacy. In: Animal and Translational Models for CNS Drug Discovery. Volume 3 - Reward Deficit Disorders, (Edited by R. A. McArthur and F. Borsini), Academic Press, pp. 271-315.
• Dawson, G.R. and Goodwin G. (2005). Experimental medicine in psychiatry. Journal of Psychopharmacology, 19, 565-566.
• Dawson, G.R., Collinson, N. and Atack, J.R. (2005). Development of subtype selective GABAA modulators. CNS Spectrums, 10, 21-27.
• Vickers, S.P. and Dourish, C.T. (2004). Serotonin receptor ligands and the treatment of obesity. Current Opinion in Investigational Drugs, 5, 377-388.

ORIGINAL PAPERS

• Schmechtig A., Lees J., Grayson L., Craig K. J., Dadhiwala R., Dawson G.R., Deakin J.F.W., Dourish C.T, Koychev I, McMullen K, Migo E.M., Perry C., Wilkinson L., Morris R., Williams S.C.R., Ettinger U. (2013). Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy. Psychopharmacology Epub 2013 February 22.
• Harmer, C.J., Dawson, G.R., Dourish, C.T., Favaron, E., Parsons, E., Fiore, M., Zucchetto, M., Bifone, A., Poggesi, I., Fernandes, S., Alexander, R.C. and Goodwin, G.M. (2013). Combined NK₁ antagonism and serotonin reuptake inhibition: effects on emotional processing in humans. J Psychopharmacol. Epub 2013 February 12.
• Diaper, A., Papadopoulos, A, Rich, A.S., Dawson, G.R., Dourish, C.T., Nutt, D.J. and Bailey, J.E. (2012). The effect of a clinically effective and non-effective dose of lorazepam on 7.5% CO₂-induced anxiety. Human Psychopharmacology: Clinical and Experimental, 2012 Oct 2. [Epub ahead of print].
• A. Diaper, V. Osman-Hicks, A. Rich, K. Craig, C. Dourish, G.R. Dawson, D.J. Nutt and J.E. Bailey. (2012). Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic. J Psychopharmacol. 2012 Apr 19. [Epub ahead of print]..
• Koychev, I., McMullen, K., Lees, J., Dadhiwala, R., Grayson, L., Perry, C., Schmechtig, A., Walters, J., Craig, K.J., Dawson, G.R., Dourish, C.T., Ettinger, U., Wilkinson, L., Williams, S.C.R., Deakin, J.F.W. and Barkus, E. (2011). A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-centre double-blind placebo-controlled study. European Neuropsychopharmacology, 2011 Dec 1. [Epub ahead of print].
• Fischer, B.D., Atack, J.R., Platt, D.M., Reynolds, D.S., Dawson, G.R. and Rowlett, J.K. (2011). Contribution of GABA(A) receptors containing α3 subunits to the therapeutic-related and side effects of benzodiazepine-type drugs in monkeys. Psychopharmacology, 215, 311-9. Epub 2010 Dec 30.
• Antonova, E., Parslow, D., Brammer, M., Simmons, A., Williams, S., Dawson, G.R. and Morris R. (2011). Scopolamine disrupts hippocampal activity during allocentric spatial memory in humans: an fMRI study using a virtual reality analogue of the Morris Water Maze. Journal of Psychopharmacology, 25, 1256-1265. Epub 2010 Sep 7.
• Bailey, J.E., Dawson, G.R., Dourish, C.T. and Nutt, D.J. (2011). Validating the inhalation of 7.5% CO₂ in healthy volunteers as a human experimental medicine model of Generalised Anxiety Disorder (GAD). Journal of Psychopharmacology, 25, 1192-1198.
• Bailey, J.E., Papadopoulos., A, Diaper, A., Phillips, S., Schmidt, M.E., van der Ark, P., Dourish, C.T., Dawson, G.R. and Nutt, D.J. (2011). Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO₂ proof-of-concept experimental model of human anxiety. Journal of Psychopharmacology, 25, 1199-1206. Epub 2011 May 9.
• Harmer, C.J., de Bodinat, C., Dawson, G.R., Dourish, C.T., Waldenmaier, L., Adams, S., Cowen, P.J. and Goodwin, G.M. (2011). Agomelatine facilitates positive vs negative affective processing in healthy volunteer models. Journal of Psychopharmacology, 25, 1159-1167. Epub 2010 Jul 21.
• Atack, J.R., Hallett, D.J., Tye, S., Wafford, K.A., Ryan, C., Sanabria-Bohórquez, S.M., Eng, W.S., Gibson, R.E., Burns, H.D., Dawson, G.R., Carling, R.W., Street, L.J., Pike, A., De Lepeleire, .I, Van Laere, K., Bormans, G., de Hoon, J.N., Van Hecken, A., McKernan, R.M., Murphy, M.G. and Hargreaves R.J. (2011). Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist. Journal of Psychopharmacology, 25, 329-344. Epub 2010 Feb 15.
• Atack, J.R., Wafford, K.A., Street, L.J., Dawson, G.R., Tye, S., Van Laere, K., Bormans, G., Sanabria-Bohórquez, S.M., De Lepeleire, I., de Hoon, J.N., Van Hecken, A., Burns, H.D., McKernan, R.M., Murphy, M.G. and Hargreaves, R.J. (2011). MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans Journal of Psychopharmacology, 25, 314-328. Epub 2010 Feb 10.
• Eng, W., Atack, J.R., Bergstrom, M., Sanabria, S., Appel, L., Dawson, G.R., Sciberras, D., Hargreaves, R.J., Langstrom, B. and Burns, H.D. (2010). Occupancy of human brain GABA(A) receptors by the novel α5 subtype-selective benzodiazepine site inverse agonist α5IA as measured using [¹¹C]flumazenil PET imaging. Neuropharmacology, 59, 635-639. Epub 2010 Aug 7.
• Licata, S.C., Platt, D.M., Rüedi-Bettschen, D., Atack, J.R., Dawson, G.R., Van Linn, M.L., Cook, J.M. and Rowlett, J.K. (2010). Discriminative stimulus effects of L-838,417 (7-tert-butyl-3-(2,5-difluoro-phenyl)-6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine): role of GABA(A) receptor subtypes. Neuropharmacology, 58, 357-364. Epub 2009 Oct 22.
• Halford, J.C.G., Boyland E.J., Cooper S.J., Dovey T.M., Huda M.S.B., Dourish C.T., Dawson G.R. and Wilding, J.P.H. (2010). The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. Journal of Psychopharmacology, 24, 99-109. Epub 2008 Aug 28.
• Antonova, E., Parslow, D., Brammer, M., Dawson, G.R., Jackson, S.H. and Morris, R. (2009) Age-related neural activity during allocentric spatial memory. Memory, 17, 125-43.
• Atack, J.R., Eng, W.S., Gibson, R.E., Ryan, C., Francis, B., Sohal, B., Dawson, G.R., Hargreaves, R.J. and Burns, H.D. (2009).The plasma-occupancy relationship of the novel GABA-A receptor benzodiazepine site ligand, α5IA, is similar in rats and primates. British Journal of Pharmacology, 157, 796-803.
• Atack, J.R., Maubach, K.A., Wafford, K.A., O'Connor, D., Rodrigues, D., Evans, D.C., Tattersall, D., Chambers, M., Macleod, A.M., Eng, W.S., Ryan, C., Hostetler, E., Sanabria, S.M., Gibson, R.E., Krause, S., Burns, D., Hargreaves, R.J., Agarwal, N.G., McKernan, R.M., Murphy, G., Gingrich, K., Dawson, G.R., Musson, D. and Petty, K. (2009). In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d][1,2,4]triazine (MRK-016), a GABAA receptor α5 subtype-selective inverse agonist. Journal of Pharmacology and Experimental Therapeutics, 331, 470-484. Epub 2009 Aug 24
• Ator, N.A., Atack, J.R., Hargreaves, R.J., Burns, H.D. and Dawson, G.R. (2010). Reducing Abuse Liability of GABAA/Benzodiazepine Ligands via Selective Partial-Agonist Efficacy at α1 and α2/3 Subtypes. Journal of Pharmacology and Experimental Therapeutics, 332, 4-16. Epub 2009 Sep 29.
• Gillespie, R.J., Cliffe, I.A., Dawson, C.E., Dourish, C.T., Gaur, S., Jordan, A.M., Knight, A.R., Lerpiniere, J., Misra, A., Pratt, R.M., Roffey, J., Stratton, G.C., Upton, R., Weiss, S.M. and Williamson, D.S. (2008). Antagonists of the human adenosine A_2A receptor. Part 3: Design and synthesis of pyrazolo [3, 4-d] pyrimidines, pyrrolo [2, 3-d] pyrimidines and 6-arylpurines. Bioorganic & Medicinal Chemistry Letters, 18, 2924-2929.
• Gillespie, R.J., Cliffe, I.A., Dawson, C.E., Dourish, C.T., Gaur, S., Giles, P.R., Jordan, A.M., Knight, A.R., Lawrence, A., Lerpiniere, J., Misra, A., Pratt, R.M., Todd, R.S., Upton, R., Weiss, S.M. and Williamson, D.S. (2008). Antagonists of the human adenosine A_2A receptor. Part 2: Design and synthesis of 4-arylthieno [3, 2-d] pyrimidine derivatives. Bioorganic & Medicinal Chemistry Letters, 18, 2920-2923.
• Gillespie, R.J., Adams, D.R., Bebbington, D., Benwell, K., Cliffe, I.A., Dawson, C.E., Dourish, C.T., Fletcher, A., Gaur, S., Giles, P.R., Jordan, A.M., Knight, A.R., Knutsen, L.S.J., Lawrence, A., Lerpiniere, J., Misra, A., Porter, R.H.P., Pratt, R.M., Shepherd, R., Upton, R., Ward, S.E., Weiss, S.M. and Williamson, D.S. (2008). Antagonists of the human adenosine A_2A receptor. Part 1: Discovery and synthesis of thieno [3, 2-d] pyrimidine-4-methanone derivatives. Bioorganic & Medicinal Chemistry Letters, 18, 2916-2919.
• Morris, H.V., Dawson, G.R., Reynolds, D.S., Atack, J.R., Rosahl, T.W. and Stephens, D.N. (2008). Alpha2-containing GABA(A) receptors are involved in mediating stimulant effects of cocaine. Pharmacology Biochemistry and Behavior, 90, 9-18.
• Fradley, R.L., Guscott, M.R., Bull, S., Hallett, D.J., Goodacre, S.C., Wafford, K.A., Garrett, E.M., Newman, R.J., O'Meara, G.F., Whiting, P.J., Rosahl, T.W., Dawson, G.R., Reynolds, D.S. and Atack, J.R. (2007). Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands. Journal of Psychopharmacology, 21, 384-391.
• Nutt, D.J., Besson, M., Wilson, S.J., Dawson, G.R. and Lingford-Hughes, A.R. (2007). Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology, 53, 810-820.
• Collinson, N., Atack, J.R., Laughton, P., Dawson, G.R. and Stephens, D.N. (2006). An inverse agonist selective for alpha5 subunit-containing GABAA receptors improves encoding and recall but not consolidation in the Morris water maze. Psychopharmacology 188, 6196-6228.
• Morris, H.V., Dawson, G.R., Reynolds, D.S., Atack, J.R. and Stephens, D.N. (2006). Both alpha2 and alpha3 GABAA receptor subtypes mediate the anxiolytic properties of benzodiazepine site ligands in the conditioned emotional response paradigm. European Journal of Neuroscience, 23, 2495-2504.
• Atack, J.R., Bayley, P.J., Fletcher, S.R., McKernan, R.M., Wafford, K.A. and Dawson, G.R. (2006). The proconvulsant effects of the GABAA alpha5 subtype-selective compound RY-080 may not be alpha5-mediated. European Journal of Pharmacology, 548, 77-82.
• Atack, J.R., Bayley, P.J., Seabrook, G.R., Wafford, K.A., McKernan, R.M. and Dawson, G.R. (2006). L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors. Neuropharmacology, 51, 1023-1029
• Dawson, G.R., Maubach, K.A., Collinson, N., Cobain, M., Everitt, B.J., MacLeod, A.M., Choudhury, H.I., McDonald, L.M., Pillai, G., Rycroft, W., Smith, A.J., Sternfeld, F., Tattersall, F.D., Wafford, K.A., Reynolds, D.S., Seabrook, G.R. and Atack, J.R. (2006). An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition. Journal of Pharmacology and Experimental Therapeutics, 316, 1335-45.
• Atack, J.R., Pike, A., Marshall, G., Stanley, J., Lincoln, R., Cook, S.M., Lewis, R.T., Blackaby, W.P., Goodacre, S.C., McKernan, R.M., Dawson, G.R., Wafford, K.A. and Reynolds DS. (2006). The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxypagoclone. Neuropharmacology, 50, 677-89
• Atack, J.R., Pike, A., Clarke, A., Cook, S.M., Sohal, B., McKernan, R.M. and Dawson, G.R. (2006). Rat pharmacokinetics and pharmacy.odynamics of a sustained release formulation of the GABAA alpha5-selective compound L-655,708. Drug Metabolism and Disposition, 34, 887-93.
• Dalton, G.L., Lee, M.D., Kennett, G.A., Dourish, C.T. and Clifton, P.G. (2006). Serotonin 1B and 2C receptor interactions in the modulation of feeding behaviour in the mouse. Psychopharmacology, 185, 45-57.
• Richter, H., Adams, D.R., Benardeau, A., Bickerdike, M.J., Bentley, J., Blench, T.J., Cliffe, I.A.C., Dourish, C.T., Hebeisen, P., Kennett, G.A., Knight, A.R., Malcolm, C.S., Mattei, P., Misra, A., Mizrahi, J., Monck, N.J.T., Plancher, J.-M., Rover, S., Roffey, J.R.A., Taylor, S. and Vickers, S.P. (2006). Synthesis and biological evaluation of novel hexahydro-pyrido[3,2:4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT_2C receptor agonists Bioorganic & Medicinal Chemistry Letters, 16, 1207-1211.
• Adams, D.R., Bentley, J., Benwell, K.R., Bickerdike, M.J., Bodkin, C.D., Cliffe, I.A.C., Dourish, C.T., George, A., Kennett, G.A., Knight, A.R., Malcolm, C.S., Mansell, H.L., Misra, A., Quirk, K., Roffey, J.R.A. and Vickers, S.P.(2006). Pyrrolo(iso)quinoline derivatives as 5-HT_2C receptor agonists. Bioorganic & Medicinal Chemistry Letters, 16, 677-680.
• Dias, R., Sheppard, W.F., Fradley, R.L., Garrett, E.M., Stanley, J.L., Tye, S.J., Goodacre, S., Lincoln, R.J., Cook, S.M., Conley, R., Hallett, D., Humphries, A.C., Thompson, S.A., Wafford, K.A., Street, L.J., Castro, J.L., Whiting, P.J., Rosahl, T.W., Atack, J.R., McKernan, R.M., Dawson, G.R. and Reynolds, D.S. (2005). Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. Journal of Neuroscience, 25, 10682-10688.
• Leslie, J.C., Shaw, D., Gregg, G., McCormick, N., Reynolds, D.S. and Dawson, G.R. (2005). Effects of reinforcement schedule on facilitation of operant extinction by chlordiazepoxide. Journal of Experimental Analysis of Behavior, 84, 327-38.
• Rover, S., Adams, D.R., Benardeau, A., Bentley, J., Bickerdike, M.J., Bourson, A., Cliffe, I.A.C., Coassolo, P., Davidson, J.E.P., Dourish, C.T., Hebeisen, P., Kennett, G.A., Knight, A.R., Malcolm, C.S., Mattei, P., Misra, A., Mizrahi, J., Muller, M., Porter, R.H.P., Richter, H., Taylor, S. and Vickers, S.P.(2005). Identification of 4-methyl-1,2,3,4,10,10a-hexahyrdopyrazino[1,2-a]indoles as 5-HT_2C receptor agonists. Bioorganic & Medicinal Chemistry Letters, 15, 3604-3608.
• Lee, M.D., Somerville, E.M., Kennett, G.A., Dourish, C.T. and Clifton, P.G. (2004). Reduced hypophagic effects of d-fenfluramine and 5-HT_2C receptor agonist mCPP in 5-HT_1B receptor knockout mice. Psychopharmacology, 176, 39-49.
• Bentley, J., Adams, D.R., Bebbington, D., Benwell, K.R., Bickerdike, M.J., Davidson, J.E.P., Dawson, C.E., Dourish, C.T., Duncton, M.A.J., Gaur, S., George, A., Giles, P.R., Hamlyn, R., Kennett, G.A., Knight, A.R., Malcolm, C.S., Mansell, H.L., Misra, A., Monck, N.J.T., Pratt, R.M., Quirk, K., Roffey, J.R.A., Vickers, S.P. and Cliffe, I.A.C. (2004). Indoline derivatives as 5-HT_2C receptor agonists. Bioorganic & Medicinal Chemistry Letters, 14, 2367-2370.
• Dalton, G.L., Lee, M.D., Kennett, G.A., Dourish, C.T. and Clifton, P.G. (2004). MCPP-induced hyperactivity in 5-HT_2C receptor mutant mice is mediated by activation of multiple 5-HT receptor subtypes. Neuropharmacology, 46, 663-671.
• Lee, M.D., Somerville, E.M., Kennett, G.A., Dourish, C.T. and Clifton, P.G. (2004). Tonic regulation of satiety by 5-HT_1B receptors in the mouse: converging evidence from behavioural and c-fos immunoreactivity studies. European Journal of Neuroscience, 19, 3017-3025.

POSTERS & ABSTRACTS

• JF William Deakin, Steve Williams, Darragh Downey, Shane McKie, Guy M Goodwin, Angela Rylands, Catherine J Harmer, Kevin J Craig, Colin T Dourish, Gerard R Dawson, Dennis J McCarthy, Mark A Smith (2012). PharmacoMRI and cognitive effects of the low-trapping NMDA channel blocker AZD6765 compared with ketamine in untreated major depressive disorder. . 28th CINP World Congress of Neuropsychopharmacology in Stockholm, Sweden. 2012
• Migo, E.M., Mitterschiffthaler, M., O'Daly, O.G., Dawson, G.R., Dourish, C.T., Craig, K.J., Simmons, A., Wilcock, G.K., McCulloch, E., Jackson, S.D.H. Kopelman, M.D., Williams, S.C.R. and Morris, R.G. (2011). Alterations in working memory networks in amnestic Mild Cognitive Impairment. Program No 551.12/C47. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2011. Online.
• Koychev, I., McMullen, K., Lees, J., Grayson, L., Schmechtig, A., Dourish, C., Wilkinson, L., Williams, S., Deakin, J.F.W. and Barkus, E. (2011). A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy. European Neuropsychopharmacology, 21, Suppl. 1, S86.
• Deakin, J.F.W., Schmechtig, A., Dourish, C.T., Craig, K.J., Dawson, G.R., Williams, S.C.R., Lees, J., Wilkinson, L. and Ettinger U. (2010). Effects of high schizotypy on control of eye movements: modulation by antipsychotic drugs and nicotine. 49th Annual Meeting of the American College of Neuropsychopharmacology. Hollywood, FL: ACNP, 2010. Online.
• Goodwin, G.M., Craig, K.J., Dawson, G.R., Dourish, C.T., Kumar, P., Favaron, E. and Harmer C.J. (2010). Effects of cognitive and neural negative biases present in Dysphoric volunteers on an emotional test battery and the associated modulation of fMRI BOLD signals. 49th Annual Meeting of the American College of Neuropsychopharmacology. Hollywood, FL: ACNP, 2010. Online.
• Goodwin, G.M., De Bodinat, C., Dawson, G.R., Dourish, C.T., Waldenmaier, L., Adams, S., Cowen, P.J., and Harmer, C.J. (2010). Agomelatine facilitates positive vs negative affective processing in healthy volunteer models. European Neuropsychopharmacology, 20, Suppl. 3, S379.
• McMullen, K., Barkus, E., Daly, O.G.O., Kumari, V., Dawson, G.R., Dourish, C.T., Craig, K.J., Williams, S.C.R. and Morris, R.G. (2010). The neural correlates of allocentric spatial memory performance across the schizotypal personality spectrum. Program No. 886.19/VV12. 2010 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2010. Online.
• Kumar, P., Craig, K.J., Favaron, E., Dawson, G.R., Dourish, C.T., Goodwin, G.M. and Harmer C.J. (2010). Neural processing of emotional information is negatively biased in dysphoria. Program No. 886.18/VV13. 2010 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2010. Online.
• Schmechtig, A., Dourish, C.T., Craig, K.J., Dawson, G.R., Williams, S.C.R., Deakin, J.F.W., Lees, J., Wilkinson, L. and Ettinger U. (2010). Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by high schizotypy. Program No. 886.18/VV11. 2010 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2010. Online.
• Harmer, C.J., De Bodinat, C., Dawson, G.R., Waldenmaier, L., Adams, S., Cowen, P.J., Goodwin, G.M. and Dourish, C.T. (2009). Agomelatine facilitates positive vs negative affective processing in healthy volunteer models Program No. 18.5. 2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009. Online.
• Dawson, G.R., Bailey, J.E., Papadopoulos, A, Diaper, A., Phillips, S.M., Schmidt, M., Van Der Ark, P., Dourish, C.T. and Nutt, D.J. (2009). Preliminary evidence of efficacy of a CRF1 receptor antagonist in the 7.5% CO2 model of anxiety.  Program No. 250.5/01. 2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009. Online.
• Halford, J.C.G., Boyland, E., Dovey, T.M., Huda, M., Dourish, C.T., Dawson, G.R. and Wilding, J.P.H. (2007). A double-blind, placebo-controlled crossover study to quantify the effects of sibutramine on energy intake and energy expenditure in obese subjects during a test meal using a Universal Eating Monitor (UEM) method. International Journal of Obesity 31, Suppl. 1, T3PO,188s151.
• Dourish C.T., Boyland, E., Halford J.C.G., Dawson, G.R., Wilding, J.P.H. (2006) Assessment of the potential efficacy and CNS side-effects of novel serotonergic anti-obesity agents in Phase 1 clinical studies. Journal of Pharmacological Sciences 101, Suppl. 1, 17.

P1vital, the P1vital logo and all other P1vital product or service names
are registered trade marks of P1vital Limited. © P1vital Limited. All rights reserved.